MANKIND
MANKIND PHARMA LIMITED
Each stock's 10,000-path forecast, rendered as light.
MANKIND PHARMA LIMITED (MANKIND) Stock Analysis & Case Study
Is MANKIND a good buy? The data-driven verdict.
MANKIND PHARMA LIMITED (MANKIND) trades at ₹2,456,on the numbers it mixed signals, a Downstox Snapshot Score of 49/100.
On the numbers, MANKIND PHARMA LIMITED (MANKIND) mixed signals, a Downstox Snapshot Score of 49/100, weighing expensive at 47.6× earnings, ROE of 13.1%, a 60% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
MANKIND fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How MANKIND ranks against the 2,373 companies in our screener
- MANKIND's market cap of 1.01L Cr ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MANKIND's book value of ₹395 ranks in the 86th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MANKIND's promoter holding of 72.6% ranks in the 81st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MANKIND's 3-year profit (PAT) growth of 17.0% ranks in the 52nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MANKIND's 3-year revenue growth of 18.0% ranks in the 69th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MANKIND's debt-to-equity ratio of 0.39x is lower than 43% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is MANKIND overvalued? MANKIND P/E vs its Pharma
MANKIND's P/E of 47.6× sits above the Pharma peer median of 33.0×, so on earnings it screens richer than peers, while its 0.04% dividend yield is below the peer median of 0.68%.
MANKIND share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 3.2y of MANKIND history (17%/yr drift, 29%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MANKIND 2027 | ₹1,831 | ₹2,644 | ₹3,818 | +8% |
| MANKIND 2028 | ₹1,688 | ₹2,846 | ₹4,797 | +16% |
| MANKIND 2029 | ₹1,599 | ₹3,064 | ₹5,869 | +25% |
| MANKIND 2030 | ₹1,535 | ₹3,298 | ₹7,087 | +34% |
| MANKIND 2031 | ₹1,503 | ₹3,550 | ₹8,387 | +45% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MANKIND goes up, or doubles?
The bull case for MANKIND
- MANKIND's return on equity of 13.1% ranks in the 64th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹2,644 (+8%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹5,869.
The bear case & risks
- MANKIND's P/E of 47.6x is lower than 28% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,599.
MANKIND volatility & expected range, how bumpy is the ride?
Over the last 3.2 years MANKIND compounded at 17%/year with annualized volatility of 29%. That volatility implies a 1-year 80% range of ₹1,831-₹3,818, the honest backbone behind any single price target.
MANKIND price forecast, the full 60-month probability fan
MANKIND price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MANKIND hits common targets within the simulated horizon?
Full multi-horizon detail on the MANKIND price target & forecast page.
MANKIND Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. MANKIND scores 6/8, mixed financial health.
MANKIND MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy MANKIND with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 25.04% | 4.0× |
| Zerodha | 24.30% | 4.1× |
| Groww | 24.36% | 4.1× |
| Dhan | 23.00% | 4.3× |
| Kotak NeoCHEAPEST | 21.55% | 4.6× |
| Paytm Money | 21.62% | 4.6× |
| Pocketful | 28.45% | 3.5× |
| Anand Rathi | 28.53% | 3.5× |
| Bajaj Broking | 23.00% | 4.3× |
| Share India | 28.59% | 3.5× |
Compare every broker on the MANKIND MTF page.
MANKIND vs peers,Pharma comparison
| Stock | P/E | Div yield | Market cap |
|---|---|---|---|
| MANKIND (this stock) | 47.6× | 0.04% | ₹1.01L Cr |
| SUNPHARMA | 36.9× | 0.82% | ₹4.67L Cr |
| DIVISLAB | 73.7× | 0.36% | ₹2.20L Cr |
| DRREDDY | 30.4× | 0.68% | ₹97,824 Cr |
| CIPLA | 33.0× | 0.89% | ₹1.18L Cr |
| LUPIN | 18.2× | 0.76% | ₹1.08L Cr |
| AUROPHARMA | 25.5× | 0.24% | ₹96,297 Cr |
Fundamentals from Screener.in, as of 9 Aug 2026
About MANKIND PHARMA LIMITED: sector, index & market-cap context
MANKIND PHARMA LIMITED (MANKIND) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 500 index, with a market capitalisation of ₹1.01L Cr. See more stocks on our screener.
How the MANKIND Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of MANKIND PHARMA LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MANKIND analysis, FAQs
Is MANKIND PHARMA LIMITED (MANKIND) a good buy?
On the numbers, MANKIND PHARMA LIMITED (MANKIND) mixed signals, a Downstox Snapshot Score of 49/100, weighing expensive at 47.6× earnings, ROE of 13.1%, a 60% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MANKIND overvalued or undervalued?
MANKIND trades at 47.6× earnings versus a peer median of 33.0×, so it screens richer than its Pharma peers.
What is the MANKIND share price target for 2031?
MANKIND's probability-weighted 2031 median target is ₹3,550, with an 80% range of ₹1,503-₹8,387 (10,000-path Monte-Carlo).
What is the probability MANKIND doubles in 5 years?
The modelled probability of MANKIND reaching ₹4,912 (2×) within 5 years is 31%.
What is the bull case for MANKIND?
MANKIND's return on equity of 13.1% ranks in the 64th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A 10,000-path probability model puts a 60% chance the price is higher in a year, with a median target of ₹2,644 (+8%).
What are the risks in MANKIND?
MANKIND's P/E of 47.6x is lower than 28% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.